<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892499</url>
  </required_header>
  <id_info>
    <org_study_id>OLI-105</org_study_id>
    <nct_id>NCT03892499</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers</brief_title>
  <official_title>An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of Olinciguat (IW-1701)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclerion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclerion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of itraconazole (a potent cytochrome P450 isoenzyme [CYP]3A inhibitor)
      on the pharmacokinetics (PK) of olinciguat
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">June 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of olinciguat</measure>
    <time_frame>Predose and up to 8 days post first olinciguat dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from time zero (predose) extrapolated to infinity (AUCinf)</measure>
    <time_frame>Predose and up to 8 days post first olinciguat dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with â‰¥1 treatment-emergent adverse event (TEAE) in Period 1 vs Period 2</measure>
    <time_frame>51 days post first olinciguat dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Itraconazole</measure>
    <time_frame>First Itraconazole dose up to day 8 of Period 2 (Period 2 duration can be up to 13 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve during a dosing interval (AUCtau) for itraconazole and hydroxy-itraconazole</measure>
    <time_frame>Period 2 (Period 2 duration can be up to 13 days) predose and up to 24 hour after 2nd olinciguat dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of hydroxy-Itraconazole</measure>
    <time_frame>First Itraconazole dose up to day 8 of Period 2 (Period 2 duration can be up to 13 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single dose of olinciguat. Period 2: ITZ is dosed once daily (QD) for 10 days; a single dose of olinciguat is administered 1 hour after the fourth ITZ QD dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olinciguat</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <other_name>IW-1701</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an ambulatory adult and between 18 and 55 years old (inclusive) at the
             screening visit

          -  Subject is in good health and has no clinically significant findings on physical
             examination

          -  Body mass index is &gt; 18 and &lt; 30 kg/m2 at the screening visit

          -  Women of reproductive potential must have a negative pregnancy test at screening at at
             the time of check-in and must agree to use protocol-specified contraception throughout
             the duration of the study and until 90 days after receiving the final study drug dose

          -  Men must agree to use protocol-specified contraception and also to not donate sperm
             throughout the study and until 90 days after receiving the final study drug dose

          -  Other inclusion criteria per protocol

        Exclusion Criteria:

          -  Any active or unstable clinically significant medical condition

          -  Use of any prescribed or non-prescribed medication (except for hormonal birth control)

          -  Other exclusion criteria per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bina Tejura, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cyclerion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

